Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study.

Content Provider	Europe PMC
Author	Gargiulo, Luigi Ibba, Luciano Pavia, Giulia Vignoli, Carlo Alberto Piscazzi, Francesco Valenti, Mario Sanna, Federica Perugini, Chiara Avagliano, Jessica Costanzo, Antonio Narcisi, Alessandra
Abstract	IntroductionRisankizumab is a humanized monoclonal antibody that selectively targets interleukin-23. It is approved for treatment of moderate-to-severe plaque psoriasis. We conducted a 52-week monocentric retrospective study to evaluate the effectiveness and safety of risankizumab in a real-life setting.MethodsOur study included 131 adults with moderate-to-severe plaque psoriasis all treated with risankizumab for at least 52 weeks. Patient characteristics and PASI (Psoriasis Area and Severity Index) at each visit were recorded. The percentages of patients achieving 75%/90%/100% (PASI 75/90/100) improvement in PASI with respect to baseline were registered.ResultsAt week 52, 93.9%, 78.6%, and 61.1% of patients achieved PASI 75/90/100, respectively. An absolute PASI ≤ 2 was reached by 90.8% at week 52. The higher body mass index and the presence of cardio-metabolic comorbidities did not interfere with the odds of reaching PASI 75/90/100 at each time-point. At week 52, comparable percentages of patients achieved PASI 100, regardless of the involvement of difficult-to-treat-areas. No significant safety findings were recorded and none of the patients had to interrupt the treatment because of adverse events.ConclusionsOur findings confirmed that risankizumab is a safe and effective therapeutic option for the treatment of a wide “real-life” cohort of patients with psoriasis.
ISSN	21938210
Journal	Dermatology and Therapy
Volume Number	12
PubMed Central reference number	PMC9443623
Issue Number	10
PubMed reference number	36063283
e-ISSN	21909172
DOI	10.1007/s13555-022-00795-x
Language	English
Publisher	Springer Healthcare
Publisher Date	2022-09-05
Publisher Place	Cheshire
Access Restriction	Open
Rights License	Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. © The Author(s) 2022
Subject Keyword	Anti-IL-23 Biologics Psoriasis Real-life Risankizumab
Content Type	Text
Resource Type	Article
Subject	Dermatology